TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3948048

Group type: EXPERIMENTAL
Intervention: Droperidol (50 micrograms . kg‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (7.5 micrograms . kg‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms . kg‐1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline (control for droperidol)
Number of subjects: 64
Study: 3232105

Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to air dried surfaces for 6 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to water-wetted surfaces for 6 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duraphat varnish applied to saliva-wetted surfaces for 6 hours
Number of subjects: 30
Study: 31929465

Group type: EXPERIMENTAL
Intervention: Attitudes Toward Mood Stabilizers Questionnaire (AMSQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets Routine Questionnaire (TRQ)
Number of subjects: 0
Study: 31216949

Group type: EXPERIMENTAL
Intervention: 3-day preoperative protein-calorie restriction regimen (30% calorie/70% protein restriction)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ad libitum group
Number of subjects: 4
Study: 26914856

Group type: EXPERIMENTAL
Intervention: Structured transfer training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 25963380

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2000 mg) with air breathing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo with 40% O2 breathing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (2000 mg) with 40% O2 breathing
Number of subjects: 10
Study: 23053702

Group type: EXPERIMENTAL
Intervention: Roth 811 sealer (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AH26 (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GuttaFlow (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epiphany SE (Group 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group 5)
Number of subjects: 80
Study: 21654701

Group type: EXPERIMENTAL
Intervention: Oat bran (control +102 g oat bran/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (low-fiber diet)
Number of subjects: 24
Study: 18053054

Group type: EXPERIMENTAL
Intervention: Local wound care with 500 mg of levofloxacin by mouth daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Local wound care alone
Number of subjects: 82
Study: 16512787

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering (decrease in SBP from 141±11 mmHg to 133±12 mmHg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Improved glycaemic control (reduced HbA(1c) after 12 months)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Changes in left ventricular mass
Number of subjects: 48
Study: 12915396

Group type: EXPERIMENTAL
Intervention: Meal containing [3H]triolein consumed by patients before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meal containing [3H]triolein consumed by normal, healthy volunteers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omental fat as a surrogate for visceral fat
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous fat depots
Number of subjects: 20
Study: 11053705

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 150
Study: 8881091

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 28
Study: 1733879

Group type: EXPERIMENTAL
Intervention: Ionic high‐osmolar contrast medium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonionic low‐osmolar contrast medium
Number of subjects: 100
Study: 2861630

Group type: EXPERIMENTAL
Intervention: Broxaterol 0.250 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Broxaterol 0.500 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol 4 mg
Number of subjects: 10
Study: 27485140

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study: 26873712

Group type: EXPERIMENTAL
Intervention: 60% ASiR
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30% ASiR
Number of subjects: 40
Study: 25025755

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg BID
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID
Number of subjects: 593

Group type: COMPARATOR
Intervention: Imatinib 400 mg daily
Number of subjects: 593
Study: 23063390

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 4 weeks consolidation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 8 weeks consolidation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis with 0.5-mm distraction applied twice a day (1 mm/d) for 5 mm lengthening followed by 12 weeks consolidation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (nonoperated hemimandibles of 6 rabbits)
Number of subjects: 21
Study: 20408074

Group type: EXPERIMENTAL
Intervention: Combigan drops (brimonidine 0.2 % and timolol 0.5 %)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo drops (artificial tears)
Number of subjects: 88
Study: 18987758

Group type: EXPERIMENTAL
Intervention: Hydration alone
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Hydration plus one-time hemodialysis
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Hydration plus N-acetylcysteine
Number of subjects: 412
Study: 16429868

Group type: EXPERIMENTAL
Intervention: SmartClip brackets
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional twin brackets
Number of subjects: 58
Study: 11293556

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Hydrocodone 10 mg/acetaminophen 1000 mg
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 10078088

Group type: EXPERIMENTAL
Intervention: cilazapril 1 mg daily
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: captopril 25 mg three times daily
Number of subjects: 367

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 367
Study: 8077542

Group type: EXPERIMENTAL
Intervention: QRS + 100 shock (delivered 100 ms after QRS onset)
Number of subjects: 15

Group type: COMPARATOR
Intervention: QRS + 0 shock (delivered at QRS onset)
Number of subjects: 15
Study: 2582725

Group type: EXPERIMENTAL
Intervention: Ouabain (Na+/K+ ATPase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentolamine (alpha-adrenoceptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bretylium tosylate (neurotransmitter blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine (vasodilator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline (postsynaptic vascular alpha-adrenoceptor stimulator)
Number of subjects: 0
Study: 4361353

Group type: EXPERIMENTAL
Intervention: CP‐20,961 (interferon inducer)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CP‐20,961
Number of subjects: 29
Study: 30834725

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri, salivarius and acidophilus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with xylitol
Number of subjects: 60
Study: 28267039

Group type: EXPERIMENTAL
Intervention: Baroreceptor-activating therapy (BAT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (BAT off)
Number of subjects: 16
Study: 26931635

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 227
Study: 24727325

Group type: EXPERIMENTAL
Intervention: LCS6 G-allele carriers (n = 432 blood samples, n = 143 tumor samples)
Number of subjects: 2834

Group type: COMPARATOR
Intervention: LCS6 T-allele carriers (n = 2,402 blood samples, n = 834 tumor samples)
Number of subjects: 2834
Study: 22012877

Group type: EXPERIMENTAL
Intervention: High-speed power training (HSPT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Slow-speed strength training (SSST)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 19946241

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/daily for 2 months and 10 mg for the next 4 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 68
Study: 17185309

Group type: EXPERIMENTAL
Intervention: Intermediate non-manual occupations
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Lower officials and foremen
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Semiskilled and skilled workers
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Unskilled workers
Number of subjects: 6999

Group type: EXPERIMENTAL
Intervention: Men with a principal diagnosis of HF (n=516)
Number of subjects: 6999
Study: 11561740

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 mcg every 6 hours
Number of subjects: 58

Group type: COMPARATOR
Intervention: Misoprostol 50 mcg every 4 hours
Number of subjects: 58
Study: 9628277

Group type: EXPERIMENTAL
Intervention: CoQ10 treatment (150 mg daily for 3 years)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CoQ10 treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (16 MIDD patients, 5 mutant IGT, and 5 mutant NGT subjects)
Number of subjects: 28
Study: 8208451

Group type: EXPERIMENTAL
Intervention: Laryngotracheal topical spray of lidocaine 4% (2 ml) in Group L
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline in Group F (control)
Number of subjects: 20
Study: 2530945

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 to 10 mg orally twice a day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Propranolol (60 to 240 mg orally twice a day)
Number of subjects: 78
Study: 4578361

Group type: EXPERIMENTAL
Intervention: PAS plus isoniazid daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptomycin plus isoniazid twice a week for 1 year, then once a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of chemotherapy beyond 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 months sanatorium treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 months sanatorium treatment
Number of subjects: 0
Study: 30739389

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist–provided services
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 40
Study: 26786187

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (moderate intensity, 3 times per week for 16 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-exercise hypotension
Number of subjects: 46
Study: 26021752

Group type: EXPERIMENTAL
Intervention: High EGFR protein expression
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Increased HER4 mRNA expression
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: EGFR protein expression
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Combination of high EGFR, high HER2, low HER3 and low HER4 mRNA expression
Number of subjects: 663
Study: 23647408

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for 6 weeks on acupoints Baihui (DU20) and Zusanli (ST36)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day) for 6 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) for 6 weeks on acupoints Taichong (LR3), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7)
Number of subjects: 75
Study: 21427654

Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day for six months
Number of subjects: 23

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 23
Study: 19371942

Group type: EXPERIMENTAL
Intervention: Bilateral varicocelectomy (BV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Left varicocelectomy (LV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison of BV and LV
Number of subjects: 104
Study: 17404487

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) with methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 15082202

Group type: EXPERIMENTAL
Intervention: Epirubicin 20mg/40ml (Group A)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Epirubicin 30mg/40ml (Group B)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Epirubicin 40mg/40ml (Group C)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Epirubicin (all groups)
Number of subjects: 622
Study: 11176737

Group type: EXPERIMENTAL
Intervention: Hospital-based attending physicians
Number of subjects: 4456

Group type: COMPARATOR
Intervention: Clinic-based attending physicians
Number of subjects: 4456
Study: 10437209

Group type: EXPERIMENTAL
Intervention: Blood-letting puncture with cupping
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 1980826

Group type: EXPERIMENTAL
Intervention: Neuroleptic and antiparkinsonian medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7033746

Group type: EXPERIMENTAL
Intervention: Vitamin C tablets taken daily for 100 days
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo taken daily for 100 days
Number of subjects: 190
Study: 30488144

Group type: EXPERIMENTAL
Intervention: Intervention addressing clinician burnout
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Intervention addressing clinician interactions with consumers
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study: 27256372

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26424232

Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 259
Study: 25358723

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme (PC programme)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study: 22008447

Group type: EXPERIMENTAL
Intervention: Citalopram (≤ 60 mg/day) for up to 14 weeks
Number of subjects: 2850
Study: 20158007

Group type: EXPERIMENTAL
Intervention: AR splint (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliance (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Control Group)
Number of subjects: 50
Study: 18618513

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 153
Study: 16089275

Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg L-crystalline tyrosine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12052998

Group type: EXPERIMENTAL
Intervention: MDT care
Number of subjects: 152

Group type: COMPARATOR
Intervention: ICP
Number of subjects: 152
Study: 10593374

Group type: EXPERIMENTAL
Intervention: Midluteal start of leuprolide acetate (LA) 1 mg/d, reduced to 0.5 mg/d after addition of gonadotropins (LUT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Oral contraceptive (OC) pills until cycle day 0 followed by 20 microg of LA every 12 hours on cycle day 3 with addition of gonadotropins on cycle day 5 (MICRO)
Number of subjects: 170

Group type: COMPARATOR
Intervention: MICRO
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: LUT
Number of subjects: 170
Study: 8970626

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg/day of IVIg for the first 5 days after transplantation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no IVIg treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IVIg infusion
Number of subjects: 41
Study: 1593552

Group type: EXPERIMENTAL
Intervention: 1 mg of PGF2 alpha diluted to 20 mL in normal saline
Number of subjects: 54

Group type: COMPARATOR
Intervention: 20 mL of normal saline alone
Number of subjects: 54
Study: 2932299

Group type: EXPERIMENTAL
Intervention: EE/NG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11
Study: 30688871

Group type: EXPERIMENTAL
Intervention: Back Squat (BS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Front Squat (FS)
Number of subjects: 11
Study: 29348196

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 27290652

Group type: EXPERIMENTAL
Intervention: DHA supplementation (450 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24395136

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (poor responders)
Number of subjects: 27
Study: 22878166

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 161
Study: 19931895

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg or 8 mg once daily
Number of subjects: 883

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 883
Study: 17499425

Group type: EXPERIMENTAL
Intervention: hK2 and percent free PSA
Number of subjects: 91
Study: 15642030

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL) using a cone‐shaped glass fiber tip at an energy setting of 100 mJ/pulse and 10 pps
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical debridement using plastic curettes and antiseptic therapy with chlorhexidine digluconate (0.2%) (C)
Number of subjects: 20
Study: 12065466

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin daily for 6 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post cessation of melatonin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Serum gonadotropin levels
Number of subjects: 8
Study: 9468235

Group type: EXPERIMENTAL
Intervention: Emulsified diazepam
Number of subjects: 211

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 211
Study: 7597663

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: AMP
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 91
Study: 2103708

Group type: EXPERIMENTAL
Intervention: Systemic nimodipine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 58
Study: 760732

Group type: EXPERIMENTAL
Intervention: Chlorpropamide suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpropamide tablet formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (all formulations)
Number of subjects: 0
Study: 30836951

Group type: EXPERIMENTAL
Intervention: Guided 12-week web-based intervention (Group 1; n=65)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Standardized institutional rehabilitation program (Group 2; n=52)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Support provided by voluntary caregiver associations (Group 3; n=39)
Number of subjects: 156
Study: 28116765

Group type: EXPERIMENTAL
Intervention: Routine treatment with 600 mg/d α-lipoic acid intravenously (α-LA group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine treatment (DM group)
Number of subjects: 62
Study: 25537278

Group type: EXPERIMENTAL
Intervention: TARGET 1® (active formulation)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 23770108

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (4 days/week at 60%-65% HRmax)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (4 days/week at 80%-85% HRmax)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (wait-listed controls)
Number of subjects: 126
Study: 21305444

Group type: COMPARATOR
Intervention: Control warm-up at 8.00 am
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control warm-up at 4.00 pm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Extended warm-up at 8.00 am
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Extended warm-up at 4.00 pm
Number of subjects: 8
Study: 19255334

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR) 375 mg/m² once per week for 4 weeks every 6 months for 2 years
Number of subjects: 311

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 311
Study: 17269368

Group type: EXPERIMENTAL
Intervention: Chronic asthma patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Seasonal allergic rhinitis patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 42
Study: 15643684

Group type: EXPERIMENTAL
Intervention: Recombinant LH supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 0
Study: 11584994

Group type: EXPERIMENTAL
Intervention: Chemotherapy for primary and secondary prevention of toxoplasmosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening of seronegative pregnant women
Number of subjects: 0
Study: 9042993

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cisapride and Placebo
Number of subjects: 121
Study: 8003313

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2955672

Group type: EXPERIMENTAL
Intervention: Doxazosin (DOX), 10.8 mg daily
Number of subjects: 115

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 89.1 mg daily
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Doxazosin (DOX)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 115